Sudmedica SA is a company brings health care and services to people in those places in Chile where the offer is deficient, with affordable prices for high-standard services. It offers variety of specialities such as Pathological anatomy, Bronchopulmonary, Cardiology Surgery,Head and Neck Surgery,Breast Surgery, Maxillofacial Surgery.
2017
n/a
Last FY Revenue $0.2M
Last FY EBITDA -$12K
$28.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Sudmedica reported revenue of $0.2M and EBITDA of -$12K.
Sudmedica expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Sudmedica valuation multiples based on analyst estimatesNTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|
Revenue | XXX | $0.2M | XXX | XXX | XXX |
Gross Profit | XXX | $31K | XXX | XXX | XXX |
Gross Margin | XXX | 17% | XXX | XXX | XXX |
EBITDA | XXX | -$12K | XXX | XXX | XXX |
EBITDA Margin | XXX | -6% | XXX | XXX | XXX |
EBIT | XXX | -$0.4M | XXX | XXX | XXX |
EBIT Margin | XXX | -200% | XXX | XXX | XXX |
Net Profit | XXX | -$0.1M | XXX | XXX | XXX |
Net Margin | XXX | -46% | XXX | XXX | XXX |
Net Debt | XXX | $6K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sudmedica has current market cap of CLP 27.4B (or $28.7M), and EV of CLP 27.4B (or $28.7M).
As of September 23, 2025, Sudmedica's stock price is CLP 800000 (or $838).
See Sudmedica trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$28.7M | $28.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialSudmedica's trades at 154.7x EV/Revenue multiple, and -2454.4x EV/EBITDA.
See valuation multiples for Sudmedica and 15K+ public compsAs of September 23, 2025, Sudmedica has market cap of $28.7M and EV of $28.7M.
Equity research analysts estimate Sudmedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sudmedica's P/E ratio is not available.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $28.7M | XXX | $28.7M | XXX | XXX | XXX |
EV (current) | $28.7M | XXX | $28.7M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | 154.7x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | -2454.4x | XXX | XXX | XXX |
EV/EBIT | n/a | XXX | -77.4x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | -333.4x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | -50.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSudmedica's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Sudmedica's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sudmedica's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sudmedica and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | -6% | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 216% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
Monash IVF Group | XXX | XXX | XXX | XXX | XXX | XXX |
Pacific Smiles Group | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sudmedica acquired XXX companies to date.
Last acquisition by Sudmedica was XXXXXXXX, XXXXX XXXXX XXXXXX . Sudmedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Sudmedica founded? | Sudmedica was founded in 2017. |
Where is Sudmedica headquartered? | Sudmedica is headquartered in Chile. |
Is Sudmedica publicy listed? | Yes, Sudmedica is a public company listed on SGO. |
What is the stock symbol of Sudmedica? | Sudmedica trades under SUDMEDICA ticker. |
When did Sudmedica go public? | Sudmedica went public in 2024. |
Who are competitors of Sudmedica? | Similar companies to Sudmedica include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Monash IVF Group. |
What is the current market cap of Sudmedica? | Sudmedica's current market cap is $28.7M |
Is Sudmedica profitable? | Yes, Sudmedica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.